Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Medovex Corp. (HCYT : OTC)
 
 • Company Description   
H-CYTE Corporation builds and develops a diversified portfolio of medical technology products and services for patients. The company's principal product consists of DenerveX(R) System which provides long-lasting relief from pain associated with facet joint syndrome. It manages biomedical services, through Lung Health Institute. H-CYTE Corporation, formerly known as Medovex Corp., is based in Tampa, United States.

Number of Employees: 8

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.01 Daily Weekly Monthly
20 Day Moving Average: 77,799 shares
Shares Outstanding: 255.09 (millions)
Market Capitalization: $3.83 (millions)
Beta: 1.13
52 Week High: $0.09
52 Week Low: $0.01
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -45.45% -38.57%
12 Week -53.42% -48.79%
Year To Date -73.64% -48.46%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2202 N. West Shore Blvd. Ste 200
-
Tampa,FL 33602
USA
ph: 844-633-6839
fax: -
jassad@hcyte.com http://www.hcyte.com
 
 • General Corporate Information   
Officers
Michael Yurkowsky - Chief Executive Officer
Raymond Monteleone - Chairman
Jeremy Daniel - Chief Financial Officer
Richard Rosenblum - Director
Matthew Anderer - Director

Peer Information
Medovex Corp. (BJCT)
Medovex Corp. (CADMQ)
Medovex Corp. (APNO)
Medovex Corp. (UPDC)
Medovex Corp. (IMTIQ)
Medovex Corp. (CYGN)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 404124109
SIC: 3841
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/12/22
Share - Related Items
Shares Outstanding: 255.09
Most Recent Split Date: (:1)
Beta: 1.13
Market Capitalization: $3.83 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/12/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 2.37
EPS Growth
vs. Year Ago Period: -100.00%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: 1.06%
vs. Previous Quarter: 16.56%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -777.68
12/31/21 - -480.98
09/30/21 - -382.30
Current Ratio
03/31/22 - 0.12
12/31/21 - 0.04
09/30/21 - 0.10
Quick Ratio
03/31/22 - 0.12
12/31/21 - 0.04
09/30/21 - 0.10
Operating Margin
03/31/22 - -450.40
12/31/21 - -297.52
09/30/21 - -320.43
Net Margin
03/31/22 - -450.40
12/31/21 - -297.52
09/30/21 - -320.43
Pre-Tax Margin
03/31/22 - -450.40
12/31/21 - -297.70
09/30/21 - -320.43
Book Value
03/31/22 - -0.02
12/31/21 - -0.03
09/30/21 - -0.03
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©